Table 3. Participants with self-reported COVID-19 diagnosis, Kupferzell, Germany, 20 May–9 June 2020 (n = 50).
| Total | 18–49 years | ≥ 50 years | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Total (n unweighted) | 50 | 25 | 25 | ||||||
| Mean age in years (range) | 52 (19–81) | 37 (19–49) | 63 (50–81) | ||||||
| n | Column % a | 95% CI | n | Column % a | 95% CI | n | Column % a | 95% CI | |
| IgG-positive | 43 | 89.0 | 77.3–95.0 | 19 | 79.1 | 58.6–91.0 | 24 | 95.9 | 74.6–99.5 |
| IgG-positive, corrected for sensitivity 88.3% and specificity 99.2% | 43 | 100.8 | 87.4–107.7 | 19 | 89.5 | 66.0–103.1 | 24 | 108.7 | 84.3–112.8 |
| IgG-positive and prNT-positive | 34 | 71.6 | 57.3–82.6 | 13 | 54.6 | 34.3–73.5 | 21 | 83.5 | 62.5–93.9 |
| Chronic conditionsb | 19 | 45.8 | 31.5–60.9 | 6 | 29.5 | 13.2–53.6 | 13 | 57.7 | 36.5–76.5 |
| No symptoms | 2 | Nd | 2 | Nd | 0 | Nd | |||
| Mild symptoms only | 31 | 61.4 | 45.9–74.9 | 18 | 70.6 | 47.7–86.3 | 13 | 55.0 | 34.9–73.6 |
| Moderate-to-severe symptoms (pneumonia, dyspnoea/shortness of breath) | 17 | 34.4 | 21.6–49.9 | 5 | 19.2 | 7.7–40.6 | 12 | 45.0 | 26.4–65.1 |
CI: confidence interval; COVID-19: coronavirus disease; Nd: not done; OR: odds ratio; prNT: plaque reduction neutralisation tests; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a Weighted %.
b Lung or heart disease, diabetes, stroke, hypertension, immunodeficiency.
There were no indeterminate IgG results. Of note, while n are unweighted, proportions are weighted and can therefore not be calculated from the numbers in this table.